Skip to content

Webinar: Developing novel human iPSC models for atrial fibrillation

By Thomas Hutschalik, PhD candidate

Leveraging human iPSC technology for in vitro modeling of atrial fibrillation

Atrial Fibrillation (AF) is the most prevalent cardiac arrhythmia. It is a progressive, multifactorial disease, initiating with electrophysiological abnormalities and developing into morphological, structural and substrate pathologies. As the disease mechanisms are not yet fully understood, a lack of effective and lasting treatments continues.
Human-induced pluripotent stem cell (iPSC)-derivatives are a unique tool to improve in vitro investigation of AF disease mechanisms and can help elucidate new treatments. At Ncardia, we recently developed a human iPSC-based AF model to investigate the influence of inflammation and immune cells on atrial arrhythmias.
In this webinar, we will present a new coculture approach, combining human iPSC-derived atrial cardiomyocytes and macrophages to study new underlying mechanisms of AF and the effect of inflammation targeting compounds in the development of atrial arrhythmias through phenotype-rescue screening.

Webinar
5e00b263dbf84eb1-400x0-0-files-Events-WEBINAR-Poster_06_Replay-Webinar-replay-Assessment-of-drug-induced-structural-toxicity-with-human-iPSC-derived-c

Objectives:
In this webinar you will:

  1. Learn how human iPSC technology can be utilized for in vitro modeling of atrial fibrillation

  2. Gain insights into possible novel mechanisms underlying the onset of atrial fibrillation

  3. Discover new drug treatment possibilities for inflammation related arrhythmia treatment

Fill in the form below to watch the replay: